Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

662221

	registered interest
	date	14/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Electronic Cigarettes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he has taken to increase access to electronic vaping devices for people giving up smoking.
	tabling member constituency	Windsor
	tabling member printed	Adam Afriyie
	uin	907990
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>More smokers use e-cigarettes to help them quit than any other stop smoking aid.</p><p> </p><p>E-cigarettes are already very widely available for people who want to use them as part of their attempt to quit - indeed one in three smokers making a quit attempt are using an e-cigarette.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 20/12/2016 16:34:29 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1586 label Biography information for Adam Afriyie

657932

	registered interest
	date	13/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to ensure that patients with rare diseases are not negatively affected by the introduction of the £100,000 quality adjusted life year threshold for evaluating Highly Specialised Technologies.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	57387
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>We are committed to ensuring that patients with rare and ultra-rare diseases in England are able to access effective treatments.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has advised that the proposed arrangements are intended to provide clarity about the level of cost effectiveness below which funding will be made available, automatically and without delay, for highly specialised technologies that receive positive recommendations from NICE.</p><p> </p><p>Subject to the outcome of the current consultation exercise, those products that have a value proposition of above £100,000 per quality-adjusted life year will be provided with a further opportunity to be considered for use in the National Health Service, through NHS England’s annual process for deciding which new treatments and services will be routinely commissioned.</p><p> </p><p>Furthermore, the proposed changes are intended to clarify NICE’s existing responsibility to determine the period within which funding for recommended products needs to be made available by commissioners of services. This clarity should allow companies and commissioners to work on commercial arrangements in advance of and in parallel with the development of NICE technology appraisal and highly specialised technology guidance. In circumstances where this may not be possible, specific requests from commissioners to vary the timescale for the funding requirement will be considered by NICE.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 57384 57385 57386 question first answered 20/12/2016 15:55:01 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4382 label Biography information for Daniel Zeichner

657931

	registered interest
	date	13/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the potential effect of the £100,000 quality adjusted life year threshold for evaluating Highly Specialised Technologies on the access and update of new medicines for patients with very rare and complex diseases.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	57386
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>We are committed to ensuring that patients with rare and ultra-rare diseases in England are able to access effective treatments.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has advised that the proposed arrangements are intended to provide clarity about the level of cost effectiveness below which funding will be made available, automatically and without delay, for highly specialised technologies that receive positive recommendations from NICE.</p><p> </p><p>Subject to the outcome of the current consultation exercise, those products that have a value proposition of above £100,000 per quality-adjusted life year will be provided with a further opportunity to be considered for use in the National Health Service, through NHS England’s annual process for deciding which new treatments and services will be routinely commissioned.</p><p> </p><p>Furthermore, the proposed changes are intended to clarify NICE’s existing responsibility to determine the period within which funding for recommended products needs to be made available by commissioners of services. This clarity should allow companies and commissioners to work on commercial arrangements in advance of and in parallel with the development of NICE technology appraisal and highly specialised technology guidance. In circumstances where this may not be possible, specific requests from commissioners to vary the timescale for the funding requirement will be considered by NICE.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 57384 57385 57387 question first answered 20/12/2016 15:55:01 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4382 label Biography information for Daniel Zeichner

657930

	registered interest
	date	13/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the potential effect of the £100,000 quality adjusted life year threshold for evaluating Highly Specialised Technologies on equity of access and the objectives of the UK Rare Disease Strategy.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	57385
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>We are committed to ensuring that patients with rare and ultra-rare diseases in England are able to access effective treatments.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has advised that the proposed arrangements are intended to provide clarity about the level of cost effectiveness below which funding will be made available, automatically and without delay, for highly specialised technologies that receive positive recommendations from NICE.</p><p> </p><p>Subject to the outcome of the current consultation exercise, those products that have a value proposition of above £100,000 per quality-adjusted life year will be provided with a further opportunity to be considered for use in the National Health Service, through NHS England’s annual process for deciding which new treatments and services will be routinely commissioned.</p><p> </p><p>Furthermore, the proposed changes are intended to clarify NICE’s existing responsibility to determine the period within which funding for recommended products needs to be made available by commissioners of services. This clarity should allow companies and commissioners to work on commercial arrangements in advance of and in parallel with the development of NICE technology appraisal and highly specialised technology guidance. In circumstances where this may not be possible, specific requests from commissioners to vary the timescale for the funding requirement will be considered by NICE.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 57384 57386 57387 question first answered 20/12/2016 15:55:01 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4382 label Biography information for Daniel Zeichner

657936

	registered interest
	date	13/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate his Department has made of how many patients the proposed £100,000 quality adjusted life year threshold for evaluating Highly Specialised Technologies will affect.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	57384
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>We are committed to ensuring that patients with rare and ultra-rare diseases in England are able to access effective treatments.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has advised that the proposed arrangements are intended to provide clarity about the level of cost effectiveness below which funding will be made available, automatically and without delay, for highly specialised technologies that receive positive recommendations from NICE.</p><p> </p><p>Subject to the outcome of the current consultation exercise, those products that have a value proposition of above £100,000 per quality-adjusted life year will be provided with a further opportunity to be considered for use in the National Health Service, through NHS England’s annual process for deciding which new treatments and services will be routinely commissioned.</p><p> </p><p>Furthermore, the proposed changes are intended to clarify NICE’s existing responsibility to determine the period within which funding for recommended products needs to be made available by commissioners of services. This clarity should allow companies and commissioners to work on commercial arrangements in advance of and in parallel with the development of NICE technology appraisal and highly specialised technology guidance. In circumstances where this may not be possible, specific requests from commissioners to vary the timescale for the funding requirement will be considered by NICE.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 57385 57386 57387 question first answered 20/12/2016 15:55:01 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4382 label Biography information for Daniel Zeichner

658543

	registered interest
	date	14/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cadmium
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposal for a regulation of the European Parliament and the Council COM(2016)157/F1, what advice he plans to issue to consumers on the consumption of cadmium-rich food.
	tabling member constituency	South West Wiltshire
	tabling member printed	Dr Andrew Murrison
	uin	57716
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Food Standards Agency does not consider that general consumer advice on cadmium in food is necessary at this time. However the Food Standards Agency supports proportionate measures to reduce inputs of cadmium into the environment and to mitigate cadmium levels in food in order to reduce consumer exposure to this environmental contaminant to as low as is reasonably practicable.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 20/12/2016 15:31:32 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1466 label Biography information for Dr Andrew Murrison

658530

	registered interest
	date	14/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Blood: Contamination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the elapse of time was between the identification of the risk of HIV in blood products for haemophiliacs and the introduction of safety measures to minimise that risk.
	tabling member constituency	Inverness, Nairn, Badenoch and Strathspey
	tabling member printed	Drew Hendry
	uin	57561
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Department was made aware of a paper prepared by the Advisory Committee on Dangerous Pathogens in August 1983, which stated that there was “strong circumstantial evidence”, that AIDS may be transmitted by blood and blood products.</p><p> </p><p>It was in December 1984 that commercial heat-treated factor VIII, which inactivated viruses, became available in any reasonable quantity and was implemented from January 1985. Testing of all blood donations for HIV was also introduced in 1985 when suitably validated, effective tests became available and was a key factor in protecting our supply.</p><p> </p><p>New tests must be properly evaluated in terms of efficacy and the wider safety of the process, to ensure that the active element in a blood product (for example Factor VIII) is not compromised.</p><p> </p><p>Before introducing heat treatment, it was critical that a full assessment and validation of the new process was carried out.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 57556 question first answered 20/12/2016 17:01:59 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4467 label Biography information for Drew Hendry

658528

	registered interest
	date	14/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Blood: Contamination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, on what date the Government first identified the risk of HIV to haemophiliacs posed by contaminated blood products.
	tabling member constituency	Inverness, Nairn, Badenoch and Strathspey
	tabling member printed	Drew Hendry
	uin	57556
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Department was made aware of a paper prepared by the Advisory Committee on Dangerous Pathogens in August 1983, which stated that there was “strong circumstantial evidence”, that AIDS may be transmitted by blood and blood products.</p><p> </p><p>It was in December 1984 that commercial heat-treated factor VIII, which inactivated viruses, became available in any reasonable quantity and was implemented from January 1985. Testing of all blood donations for HIV was also introduced in 1985 when suitably validated, effective tests became available and was a key factor in protecting our supply.</p><p> </p><p>New tests must be properly evaluated in terms of efficacy and the wider safety of the process, to ensure that the active element in a blood product (for example Factor VIII) is not compromised.</p><p> </p><p>Before introducing heat treatment, it was critical that a full assessment and validation of the new process was carried out.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 57561 question first answered 20/12/2016 17:01:59 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4467 label Biography information for Drew Hendry

658535

	registered interest
	date	14/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Blood: Contamination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate he has made of the proportion of his Department's documents relating to the issue of contaminated blood products for haemophiliacs between 1970 and 1985 which have been destroyed.
	tabling member constituency	Inverness, Nairn, Badenoch and Strathspey
	tabling member printed	Drew Hendry
	uin	57550
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>All papers that are available for the period 1970-85, amounting to over 5,500 documents, have been published on the Department’s website. Papers from more than 30 years ago are already a matter of public record. In addition over 200 files of documents covering the period from 1986 to 1995 are available to the public through the National Archive.</p><p> </p><p>In 2006 the Department commissioned a review of all the documents held between 1970-85 relating to blood safety. The review, titled: ‘Review of documentation relating to the safety of blood products 1970-1985’ was published in May 2007 and can be found at:</p><p><a href="http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074950" target="_blank">http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074950</a></p><p> </p><p>Lord Archer’s report following his independent Inquiry covered the inadvertent destruction of documents and made clear he “discovered no evidence of malicious destruction of relevant records”.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 20/12/2016 15:52:46 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4467 label Biography information for Drew Hendry

662224

	registered interest
	date	14/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Public Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will make an assessment of the significance of the average age at death in assessing the health needs of a community; and if he will make a statement.
	tabling member constituency	Slough
	tabling member printed	Fiona Mactaggart
	uin	907988
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>We want everyone to have the same opportunity to have a long and healthy life, whoever they are, wherever they live and whatever their social circumstances.</p><p>Local areas are rightly placed to determine the health needs of their local populations and that is why the Government will give £16 billion to local government over the course of this Parliament for public health.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 20/12/2016 16:37:37 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	12 label Biography information for Fiona Mactaggart